ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2012
Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- The calcium-sensing receptor in inflammation: Recent updates.Frontiers in physiology · 2022Review
- Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism.Frontiers in pharmacology · 2022Review
- Cinacalcet and primary hyperparathyroidism: systematic review and meta regression.Endocrine connections · 2020Article
- Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.PloS one · 2020Article
- Article
- The Different Facets of Extracellular Calcium Sensors: Old and New Concepts in Calcium-Sensing Receptor Signalling and Pharmacology.International journal of molecular sciences · 2018Review
- Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism.Frontiers in endocrinology · 2018Article
- The Calcium-Sensing Receptor and the Parathyroid: Past, Present, Future.Frontiers in physiology · 2016Review
- Cross Talk between the Calcium-Sensing Receptor and the Vitamin D System in Prevention of Cancer.Frontiers in physiology · 2016Review
- Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease.Frontiers in physiology · 2016Review
- Hyperplasia in glands with hormone excess.Endocrine-related cancer · 2016Review
- The extracellular calcium-sensing receptor, CaSR, in fetal development.Best practice & research. Clinical endocrinology & metabolism · 2013Review
- An unusual case of malignancy-related hypercalcemia.International journal of general medicine · 2013Article
- Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism.Langenbeck's archives of surgery · 2013Article
- Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism.International journal of nephrology and renovascular disease · 2013Article
- The role of the calcium-sensing receptor in the pathophysiology of secondary hyperparathyroidism.NDT plus · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary hyperparathyroidism (sHPT) represents an adaptive response to progressively impaired control of calcium, phosphorus and vitamin D in chronic kidney disease (CKD). It is characterized by parathyroid hyperplasia and excessive synthesis and secretion of parathyroid hormone (PTH). Parathyroid hyperplasia in uremic rats can be prevented by calcium-sensing receptor (CaSR) activation with the calcimimetic cinacalcet (Sensipar®/Mimpara®); however, it is unknown, how long the effects of cinacalcet persist after withdrawal of treatment or if cinacalcet is efficacious in uremic rats with established sHPT.
methodsWe sought to determine the effect of cinacalcet discontinuation in uremic rats and whether cinacalcet was capable of influencing parathyroid hyperplasia in animals with established sHPT.
resultsDiscontinuation of cinacalcet resulted in reversal of the beneficial effects on serum PTH and parathyroid hyperplasia. In rats with established sHPT, cinacalcet decreased serum PTH and mediated regression of parathyroid hyperplasia. The cinacalcet-mediated decrease in parathyroid gland size was accompanied by increased expression of the cyclin-dependent kinase inhibitor p21. Prevention of cellular proliferation with cinacalcet occurred despite increased serum phosphorus and decreased serum calcium.
conclusionsThe animal data provided suggest established parathyroid hyperplasia can be reversed by modulating CaSR activity with cinacalcet and that continued treatment may be necessary to maintain reductions in PTH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.